Pelotonia is a grassroots bike tour with one goal: to end cancer
Not Yet Registered?
If you have not yet registered to participate in Pelotonia 17, click here to register as a Rider, Virtual Rider, or Volunteer.
Close Tab

Pelotonia Invests $1 Million in Statewide Endometrial Cancer Research Initiative in Ohio

Pelotonia Invests $1 Million in Statewide Endometrial Cancer Research Initiative in Ohio


Statewide InitiativesWe are excited to share that you – The Greatest Team Ever – have just made our most recent investment possible: $1 million to help our partners at the OSUCCC-James launch a statewide endometrial cancer research initiative.

The Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) initiative is expected to recruit up to 700 Ohio women through a network of at least 25 partner hospitals from communities across the state of Ohio. Patients will be screened for Lynch syndrome – a genetic disorder that dramatically increases a person’s risk for endometrial (uterine), colon, stomach and ovarian cancer – and other inherited genetic mutations linked to these cancers. At the same time, patient tumor samples will undergo molecular profiling to identify treatment approaches personalized to the patient’s unique tumor characteristics.

“We are proud to put our money where our mouth is with this important $1 million investment in the OPTEC study,” said Doug Ulman, Pelotonia President & CEO. “Every dollar raised goes directly to fund critical cancer research and this study puts us one step closer to our goal to end cancer. We are grateful to every Rider, Virtual Rider and Volunteer whose contributions have funded this exciting new project that has the potential to positively impact the health of women far beyond the borders of Ohio.”

The OPTEC study is the third statewide cancer research project funded by Pelotonia. Other Pelotonia-funded projects include The Ohio Colorectal Cancer Screening and Prevention Initiative and Beating Lung Cancer in Ohio.

Did You Know?

  • More than 61,000 women are diagnosed with endometrial cancer annually across the United States, with more than 17 percent of patients dying of the disease.
  • Up to five percent of all women with endometrial cancer have inherited Lynch syndrome. The lifetime risk for endometrial cancer in a woman with Lynch syndrome is 50 percent, which is 10 times higher than a woman without Lynch syndrome.
  • Women with Lynch syndrome have a similar risk for colon cancer as they do endometrial cancer.
  • Implementing universal screening for Lynch Syndrome across the United States was recently announced as one of the recommendations identified by the Cancer Moonshot Blue Ribbon Panel.

About the OPTEC study

  • The study seeks to test endometrial cancer patients in Ohio for Lynch syndrome using a novel genetic sequencing technique developed by scientists at the OSUCCC – James and Nationwide Children’s Research Institute.
  • It will also help Lynch syndrome patients – and at-risk family members – understand the importance of genetic testing and cancer-prevention strategies based on their increased risk for Lynch syndrome-associated cancers.
  • Researchers will also create a patient registry to track endometrial cancer patients from the current study, colon cancer patients (identified through another statewide cancer research initiative of the OSUCCC – James) as well as affected family members to help increase compliance with follow-up care for cancer prevention.

Helping Patients

  • Despite professional recommendations from the Society for Gynecologic Oncology and the American College of Obstetrics and Gynecology for universal Lynch syndrome screening in endometrial cancer patients, newly diagnosed patients with endometrial cancer are often not screened for Lynch syndrome.
  • All participants will receive complete, upfront gene sequencing to test for Lynch syndrome and other inherited genetic mutations with known links to cancer.
  • Genomic profiling through this study will also help identify patients most likely to benefit from new medical therapies, including immunotherapy drugs that target PD-1. The drugs that target PD-1 have emerged in recent years as promising and effective approaches to treating solid tumors from patients with Lynch syndrome.

To learn more about the study enrollment, call The James Line at 1-800-293-8066.

 

 

 

Bookmark and Share
0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *